Abstract

Obesity and type 2 diabetes (T2D) arise from complex, tissue-specific pathologies spanning adipose 
inflammation, ectopic lipid deposition, hepatic insulin resistance, and microvascular dysfunction. Conventional 
diagnostics detect late-stage complications and provide limited spatial resolution of disease activity, while 
therapeutics often lack tissue selectivity and dynamic control. Nanotheranostics as a single platform that 
integrate targeted imaging and therapy offers a route to earlier detection and precision intervention. Engineered 
nanoparticles can home to metabolically diseased tissues, amplify multimodal imaging signals, and release drugs 
in response to biochemical cues such as pH, enzymes, or redox gradients. By coupling quantification and 
treatment within the same construct, nanotheranostics enable dose individualization, on-treatment monitoring, 
and adaptive regimens guided by imaging readouts. This review outlines biological rationales for theranostic 
targeting in metabolic disease; surveys contrast chemistries and imaging modalities suited to adipose, liver, 
pancreas, muscle, and vasculature; details stimuli-responsive designs that synchronize drug release with 
pathologic microenvironments; and examines safety, manufacturability, and regulatory pathways. We propose 
clinical trial frameworks that incorporate quantitative imaging endpoints with glycemic and cardiometabolic 
outcomes, positioning nanotheranostics as complementary to incretins, SGLT2 inhibitors, and lifestyle 
interventions. If translated responsibly, nanotheranostics could shift obesity and T2D care from reactive 
management to proactive, image-guided precision therapy.